Adrenaline for Severe Allergies (Anaphylaxis)

Anaphylaxis is a potentially life threatening, severe allergic reaction and should always be treated as a medical emergency. Adrenaline (epinephrine) injected into the outer mid-thigh muscle is the first line of treatment for anaphylaxis. Adrenaline is a natural hormone released in response to stress. When injected, adrenaline rapidly reverses the effects of anaphylaxis by reducing throat swelling, opening the airways, and maintaining heart function and blood pressure.

pdfASCIA PCC Adrenaline for severe allergies 2016151.61 KB

Management of anaphylaxis
  • Identify and avoid the cause where possible.
  • Have an ASCIA Action Plan for Anaphylaxis and adrenaline autoinjector close by (easily accessible) to treat if accidental exposure occurs.

ASCIA Action Plans for Anaphylaxis (emergency response plan) must be completed by a doctor and should be kept with the adrenaline autoinjector as the plans include instructions on when and how to give an adrenaline autoinjector. Adrenaline autoinjectors contain a single, fixed dose of adrenaline, and have been designed to be given by non-medical people, such as a friend, teacher, early childhood education/care worker, parent, passer-by or by the patient themselves (if they are not too unwell to do this).

Use of adrenaline in anaphylaxis assists the body's natural response

The body's natural response to anaphylaxis is to release adrenaline, a natural antidote to some of the chemicals released as part of a severe allergic reaction. Therefore, injected adrenaline assists the body's natural response. As adrenaline is destroyed by enzymes in the stomach, it needs to be injected. It cannot be given by mouth, and inhaled adrenaline is ineffective. Adrenaline injected into the outer mid-thigh muscle, works rapidly to reduce throat swelling, open up the airways and maintain heart function and blood pressure. It is the only medication available for the immediate treatment of severe allergic reactions (anaphylaxis).

The potential risks of NOT giving adrenaline far outweigh the potential risks of giving adrenaline

If anaphylaxis is suspected, give the adrenaline autoinjector as not giving the adrenaline autoinjector can be more harmful than giving it, even when it may not have been necessary. If in doubt, give the adrenaline autoinjector.

Common side effects of adrenaline include increased heart rate, trembling and paleness. Therefore, someone may look unwell even after the adrenaline autoinjector has been given. Of course needles may hurt, but you have to remember why you are using it and that the adrenaline can be life-saving.

Adrenaline should be injected into the muscle of the outer mid thigh

Adrenaline is absorbed most rapidly when injected into the outer mid-thigh muscle. Injecting into the outer mid-thigh also makes it extremely unlikely that damage to any nerves or tendons will occur, or that it will be inadvertently injected into an artery or vein. It is also the least painful part of the body to give an injection.

It is important to lay the person flat – do not allow them to stand or walk. If breathing is difficult allow them to sit. If unconscious, place them in the recovery position (on their side). They must not walk to or from the ambulance even if they appear to have improved or recovered.

There are two doses of adrenaline autoinjectors available in Australia and New Zealand

Your doctor will advise which dose is required.

  • EpiPen Jr adrenaline autoinjectors (0.15mg) are usually prescribed for children weighing 10-20kg.
  • EpiPen adrenaline autoinjectors (0.3mg) are usually prescribed for children over 20kg and adults.

Each adrenaline autoinjector contains a single fixed dose of adrenaline. It is designed to be used as a first aid device by people without any medical or nursing training. Instructions for adrenaline autoinjectors are shown on the ASCIA Action Plans for Anaphylaxis that are available on the ASCIA website: www.allergy.org.au/health-professionals/anaphylaxis-resources/ascia-action-plan-for-anaphylaxis

It is important to check that you have been given the ASCIA Action Plan which matches the device you have been prescribed.

If you or your child has been prescribed an adrenaline autoinjector, it is important that you learn and practise how to use it, using a trainer device, that does not contain adrenaline. It is recommended that you practise using the trainer device at least every three to four months.

Store adrenaline at room temperature

Adrenaline autoinjectors should be stored in a cool dark place at room temperature, but NOT refrigerated as this can damage the autoinjector mechanism. Whilst they should be kept out of the reach of small children, adrenaline autoinjectors must be readily available when needed and not in a locked cupboard. The shelf life of adrenaline is normally one or two years from the date of supply. You need to regularly check the expiry date on the adrenaline autoinjector.

Further information

ASCIA anaphylaxis resources: www.allergy.org.au/health-professionals/anaphylaxis-resources

The ASCIA website www.allergy.org.au/patients/patient-support-organisations includes a list of patient organisation websites including:

© ASCIA 2019

ASCIA is the peak professional body of clinical immunology/allergy specialists in Australia and New Zealand.

ASCIA resources are based on published literature and expert review, however, they are not intended to replace medical advice. The content of ASCIA resources is not influenced by any commercial organisations.

For more information go to www.allergy.org.au

To donate to allergy research go to www.allergyimmunology.org.au

 

Content last updated 2019

Mod ASCIA Member
Donate to AIFA
go to NAS website
Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:

About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect
This website is certified by Health On the Net Foundation. Click to verify.This site complies with the HONcode standard for trustworthy health information.Verify here.